Selective CaV1.3 blockade reduces aldosterone production in human adrenocortical cells, offering a potential targeted treatment for primary hyperaldosteronism that avoids the vascular side effects of CaV1.2 blockade.
Answers are grounded in this paper and cite their sources.
Selective CaV1.3 blockade may curb aldosterone output in APA models; leaves open clinical translation versus nifedipine.
Aldosterone-producing adenomas (APAs) vary in phenotype and genotype. Zona glomerulosa (ZG)-like APAs frequently have mutations of an L-type calcium channel (LTCC) CaV1.3. Using a novel antagonist of CaV1.3, compound 8, we investigated the role of CaV1.3 on steroidogenesis in the human adrenocortical cell line, H295R, and in primary human adrenal cells. This investigational drug was compared with the common antihypertensive drug nifedipine, which has 4.5-fold selectivity for the vascular LTCC, CaV1.2, over CaV1.3. In H295R cells transfected with wild-type or mutant CaV1.3 channels, the latter produced more aldosterone than wild-type, which was ameliorated by 100 μM of compound 8. In primary adrenal and non-transfected H295R cells, compound 8 decreased aldosterone production similar to high concentration of nifedipine (100 μM). Selective CaV1.3 blockade may offer a novel way of treating primary hyperaldosteronism, which avoids the vascular side effects of CaV1.2-blockade, and provides targeted treatment for ZG-like APAs with mutations of CaV1.3.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: